EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses

Sara H Mahmoud, Ahmed A Khalil iD, Noura M Abo Shama, Marwa F El Sayed, Reem A Soliman, Naglaa M Hagag, Nahed Yehia iD, Mahmoud M Naguib iD, Abdel-Sattar Arafa iD, Mohamed A Ali, Mounir M El-Safty, Ahmed Mostafa

Vaccines · 22.08.2023 · 11 (9) · 1397

DOI: 10.3390/vaccines11091397 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 22.08.2023. Verfasst von Sara H Mahmoud und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academy of Scientific Research and Technology, National Research Centre, National Strategy for Genetic Engineering and Biotechnology, Academy of Scientific Research and Technology (ASRT), Egypt.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Controlling avian influenza viruses (AIVs) is mainly based on culling of the infected bird flocks or via the implementation of inactivated vaccines in countries where AIVs are considered to be endemic. Over the last decade, several avian influenza virus subtypes, including highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1.2, H5N8 clade 2.3.4.4b and the recent H5N1 clade 2.3.4.4b, have been reported among poultry populations in Egypt. This demanded the utilization of a nationwide routine vaccination program in the poultry sector. Antigenic differences between available avian influenza vaccines and the currently circulating H5Nx strains were reported, calling for an updated vaccine for homogenous strains. In this study, three H5Nx vaccines were generated by utilizing the reverse genetic system: rgH5N1_2.3.4.4, rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2. Further, the immunogenicity and the cross-reactivity of the generated inactivated vaccines were assessed in the chicken model against a panel of homologous and heterologous H5Nx HPAIVs. Interestingly, the rgH5N1_2.3.4.4 induced high immunogenicity in specific-pathogen-free (SPF) chicken and could efficiently protect immunized chickens against challenge infection with HPAIV H5N1_2.3.4.4, H5N8_2.3.4.4 and H5N1_2.2.1.2. In parallel, the rgH5N1_2.2.1.2 could partially protect SPF chickens against infection with HPAIV H5N1_2.3.4.4 and H5N8_2.3.4.4. Conversely, the raised antibodies to rgH5N1_2.3.4.4 could provide full protection against HPAIV H5N1_2.3.4.4 and HPAIV H5N8_2.3.4.4, and partial protection (60%) against HPAIV H5N1_2.2.1.2. Compared to rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2 vaccines, chickens vaccinated with rgH5N1_2.3.4.4 showed lower viral shedding following challenge infection with the predefined HPAIVs. These data emphasize the superior immunogenicity and cross-protective efficacy of the rgH5N1_2.3.4.4 in comparison to rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2.

Schlagwörter

Stichwörter der Autor:innen

AIV H5N1AIV H5N8clade 2.3.4.4bhighly pathogenic avian influenzaimmunogenicityvaccine

Autor:innen und Institutionen

  • Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt.
  • Veterinary Serum and Vaccine Research Institute, Agricultural Research Center (ARC), Abbasia, Cairo 11381, Egypt.
  • Central Laboratory for Evaluation of Veterinary Biologics, Agricultural Research Center (ARC), Abbasia, Cairo 11517, Egypt.
  • Reference Laboratory for Veterinary Quality Control on Poultry Production, Animal Health Research Institute, Agriculture Research Center, Giza 12618, Egypt.
  • Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, 75121 Uppsala, Sweden.
  • Texas Biomedical Research Institute, San Antonio, TX 78227, USA.

ORCID-Profile: Ahmed A Khalil, Nahed Yehia, Mahmoud M Naguib, Abdel-Sattar Arafa

Förderung

  • Academy of Scientific Research and Technology
  • National Research Centre
  • National Strategy for Genetic Engineering and Biotechnology, Academy of Scientific Research and Technology (ASRT), Egypt
  • Egyptian National Research Centre (NRC)
  • Carl Trygger Stiftelse
  • Clas Groschinskys Minnesfond
  • Åke Wibergs Stiftelse
  • Swedish Research Council for Sustainable Development-FORMAS

Zitieren

APA

Mahmoud, S. H., Khalil, A. A., Abo Shama, N. M., El Sayed, M. F., Soliman, R. A., Hagag, N. M., Yehia, N., Naguib, M. M., Arafa, A. S., Ali, M. A., El-Safty, M. M., & Mostafa, A. (2023). Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses. Vaccines, 11(9), 1397. https://doi.org/10.3390/vaccines11091397

Vancouver

Mahmoud SH, Khalil AA, Abo Shama NM, El Sayed MF, Soliman RA, Hagag NM, et al. Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses. Vaccines. 2023;11(9):1397. doi:10.3390/vaccines11091397

BibTeX
@article{Mahmoud2023,
  author = {Mahmoud, Sara H and Khalil, Ahmed A and Abo Shama, Noura M and El Sayed, Marwa F and Soliman, Reem A and Hagag, Naglaa M and Yehia, Nahed and Naguib, Mahmoud M and Arafa, Abdel-Sattar and Ali, Mohamed A and El-Safty, Mounir M and Mostafa, Ahmed},
  title = {Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses},
  journal = {Vaccines},
  year = {2023},
  volume = {11},
  number = {9},
  pages = {1397},
  doi = {10.3390/vaccines11091397}
}
Kostenlos starten →